Short Interest in GoodRx Holdings, Inc. (NASDAQ:GDRX) Drops By 13.9%

GoodRx Holdings, Inc. ( NASDAQ:GDRX – Get Free Report ) saw a significant drop in short interest in November. As of November 15th, there was short interest totalling 7,480,000 shares, a drop of 13.

9% from the October 31st total of 8,690,000 shares. Based on an average trading volume of 1,370,000 shares, the short-interest ratio is currently 5.5 days.



Approximately 8.7% of the company’s shares are short sold. GoodRx Trading Down 0.

4 % NASDAQ GDRX opened at $4.84 on Friday. The company has a debt-to-equity ratio of 0.

70, a quick ratio of 5.48 and a current ratio of 5.48.

GoodRx has a one year low of $4.09 and a one year high of $9.26.

The company’s 50-day simple moving average is $5.98 and its two-hundred day simple moving average is $7.25.

The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -161.33, a price-to-earnings-growth ratio of 3.

54 and a beta of 1.39. Wall Street Analyst Weigh In Several research firms have recently issued reports on GDRX.

Barclays lowered their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th.

Citigroup cut their target price on GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th.

Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a report on Friday, August 9th. Royal Bank of Canada restated an “outperform” rating and set a $10.

00 price objective on shares of GoodRx in a report on Friday, August 16th. Finally, UBS Group reduced their target price on GoodRx from $9.00 to $8.

50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.

com, GoodRx currently has a consensus rating of “Moderate Buy” and an average target price of $8.86. Insider Buying and Selling In other GoodRx news, major shareholder Equity Vii L.

P. Spectrum sold 10,677 shares of GoodRx stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.

86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink .

4.17% of the stock is currently owned by company insiders. Institutional Inflows and Outflows A number of hedge funds and other institutional investors have recently made changes to their positions in GDRX.

California State Teachers Retirement System increased its stake in shares of GoodRx by 5.1% during the first quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock worth $503,000 after purchasing an additional 3,444 shares in the last quarter.

Liontrust Investment Partners LLP purchased a new stake in GoodRx during the 2nd quarter worth approximately $520,000. Legato Capital Management LLC purchased a new position in shares of GoodRx in the second quarter valued at approximately $805,000. Picton Mahoney Asset Management lifted its position in shares of GoodRx by 24.

3% in the second quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock valued at $4,736,000 after acquiring an additional 118,703 shares in the last quarter. Finally, ClariVest Asset Management LLC boosted its stake in shares of GoodRx by 27.

4% in the second quarter. ClariVest Asset Management LLC now owns 195,722 shares of the company’s stock worth $1,527,000 after acquiring an additional 42,097 shares during the last quarter. Hedge funds and other institutional investors own 63.

77% of the company’s stock. About GoodRx ( Get Free Report ) GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

Further Reading Five stocks we like better than GoodRx How to Calculate Inflation Rate ServiceNow: Will the High-Flyer Finally Split in 2024? With Risk Tolerance, One Size Does Not Fit All MarketBeat Week in Review – 11/25 – 11/29 The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number These 3 Stocks Are Heavy Hitters in Alternative Asset Management Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter ..